--- title: "Goserelin" canonical_url: https://peptidelibrary.app/library/goserelin description: "Depot GnRH receptor agonist approved for advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before ablation." updated: 2026-11-07 publisher: Peptide Library notice: "Research and educational use only. Not medical advice." --- # Goserelin Goserelin is an FDA-approved GnRH receptor agonist. Goserelin is a synthetic decapeptide analog of GnRH delivered from a biodegradable implant. Continuous rather than pulsatile receptor occupancy first stimulates and then downregulates pituitary GnRH receptors, so an initial rise in gonadotropins and sex steroids is followed within about two to four weeks by sustained suppression to castrate concentrations. Depot GnRH receptor agonist approved for advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before ablation. ## Classification - Type: FDA-approved GnRH receptor agonist - Mechanism class: GnRH Modulator - Development stage: Approved product - Regulatory class: FDA-approved medicine ## Mechanism Goserelin is a synthetic decapeptide analog of GnRH delivered from a biodegradable implant. Continuous rather than pulsatile receptor occupancy first stimulates and then downregulates pituitary GnRH receptors, so an initial rise in gonadotropins and sex steroids is followed within about two to four weeks by sustained suppression to castrate concentrations. ## Properties - Molecular formula: C59H84N18O14 - Molecular weight: 1,269.4 g/mol - Studied routes: Subcutaneous ## Evidence - Evidence level: FDA Approved - Highest documented: Regulatory review (FDA label) - Human trials: 0 - Controlled human trials: 0 - Preclinical sources: 0 Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess. ### Studies 1. Cited source (title omitted: it states a dose). Regulatory label (FDA), human. Population: Men with advanced prostate cancer, or Stage T2b-T4 (B2-C) prostate cancer with flutamide and radiotherapy. Palliative treatment of advanced prostate cancer; management of locally confined prostate cancer [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3) 2. Cited source (title omitted: it states a dose). Regulatory label (FDA), human. Population: Women aged 18 and over with endometriosis; women having endometrial ablation for dysfunctional uterine bleeding. Management of endometriosis; endometrial thinning before ablation [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3) 3. Cited source (title omitted: it states a dose). Regulatory label (FDA), human. Population: Pre- and perimenopausal women with advanced breast cancer. Palliative treatment of advanced breast cancer [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3) 4. Cited source (title omitted: it states a dose). Regulatory label (FDA), human. Population: Men with advanced prostate cancer, or Stage T2b-T4 (B2-C) prostate cancer with flutamide and radiotherapy. Palliative treatment of advanced prostate cancer [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4cb3c20-2738-400a-b522-3f36f71fe6c5) ## Safety Human safety basis: FDA prescribing information ## Regulatory status Goserelin is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines. - FDA status: Approved - Availability: Prescription-Only ## Frequently asked questions ### What is Goserelin? Depot GnRH receptor agonist approved for advanced prostate cancer, breast cancer, endometriosis, and endometrial thinning before ablation. ### How does Goserelin work? Goserelin is a synthetic decapeptide analog of GnRH delivered from a biodegradable implant. Continuous rather than pulsatile receptor occupancy first stimulates and then downregulates pituitary GnRH receptors, so an initial rise in gonadotropins and sex steroids is followed within about two to four weeks by sustained suppression to castrate concentrations. ### Is Goserelin FDA approved? Yes. Goserelin is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product. ### What peptides are similar to Goserelin? Compounds most often compared with Goserelin include Leuprolide, Triptorelin, Nafarelin and Histrelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ. ## References - [Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial — Chin Med J (Engl), 2023](https://pubmed.ncbi.nlm.nih.gov/37010251/) - [Roles of Goserelin in Gynecological Disorders — Drug Des Devel Ther, 2026](https://pubmed.ncbi.nlm.nih.gov/42226753/) - [Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review — BJU Int, 2018](https://pubmed.ncbi.nlm.nih.gov/29438592/) - [Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis — Fertil Steril, 1998](https://pubmed.ncbi.nlm.nih.gov/9627292/) - [Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex) — J Endocrinol, 1984](https://pubmed.ncbi.nlm.nih.gov/6238116/) Note: Dose figures are left out of this Markdown version. See the cited sources.